BIOS Fund I, LP's Form 4 filing
Lantern Pharma Inc. (LTRN) · filed Jun 13, 2025
- Accession no.
- 0001104659-25-059528
- Filed
- Jun 13, 2025, 7:57 PM ET
- Trade date
- Jun 13, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $123.6K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BIOS Fund I, LPCIK 0001697316 | 10% Owner |
| BIOS Fund I QP, LPCIK 0001700297 | 10% Owner |
| BIOS Fund II, LPCIK 0001714576 | 10% Owner |
| BIOS Fund II QP, LPCIK 0001716869 | 10% Owner |
| BIOS Fund II NT, LPCIK 0001728851 | 10% Owner |
| Fletcher Aaron G.L.CIK 0001789490 | 10% Owner |
| Bios Equity Partners II, LPCIK 0001813313 | 10% Owner |
| Bios Equity Partners, LPCIK 0001813314 | 10% Owner |
| BIOS Advisors GP, LLCCIK 0001813844 | 10% Owner |
| BIOS Capital Management, LPCIK 0001813845 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | Common Stock | SSaleDisposed | −7,206 | $3.09 | −$22,266.54 | 189,117 | Indirect | Duplicate filing |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −12,319 | $3.09 | −$38,065.71 | 323,335 | Indirect | Duplicate filing |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −1,903 | $3.09 | −$5,880.27 | 49,957 | Indirect | Duplicate filing |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −14,218 | $3.09 | −$43,933.62 | 373,178 | Indirect | Duplicate filing |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −4,354 | $3.09 | −$13,453.86 | 114,272 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.